Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
42,678,810
-
Share change
-
+424,326
-
Total reported value
-
$129,316,367
-
Put/Call ratio
-
0%
-
Price per share
-
$3.03
-
Number of holders
-
98
-
Value change
-
-$9,423,466
-
Number of buys
-
48
-
Number of sells
-
51
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q2 2022
As of 30 Jun 2022,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
98 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
42,678,810 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Deep Track Capital, LP, PFM Health Sciences, LP, ORBIMED ADVISORS LLC, COWEN AND COMPANY, LLC, BlackRock Inc., CITADEL ADVISORS LLC, MORGAN STANLEY, VANGUARD GROUP INC, and Assenagon Asset Management S.A..
This page lists
98
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.